Lilly also will automatically cap out-of-pocket costs at $35 at participating retail pharmacies for people with commercial insurance using Lilly insulin.
Affordability, supply chain constraints and access to healthcare are on everyone’s mind these days, but for people with diabetes, these are ongoing issues.
Tzield is the first and only treatment indicated to delay the onset of stage 3 type 1 diabetes in adult and pediatric patients aged 8 years old and older with stage 2 type 1 diabetes.